


CLAIMS

1. A compound according to formula (Id)



(Id)

- 5 wherein

R1 is H and R2 is selected from one of the substituents (i) and (ii) below; or


R1 is selected from one of the substituents (i) and (ii) below and R2 is H; or

R1 and R2 are both represented by substituent (i) below; or


R1 and R2 are both represented by substituent (ii) below; or

- 10 R1 is substituent (i) and R2 is substituent (ii); or

R1 is substituent (ii) and R2 is substituent (i);



(i)



(ii)

- 15 wherein * indicates the attachment point; and

wherein the carbon atom at the attachment point on substituent (i) is in the S-configuration;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein the compound is selected from the group consisting of:
- 20

(Id-ia): (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid;

(Id-ib): (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid;

(Id-iaa): (4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl hydrogen sulfate;


(Id-iib): (4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-yl)hydrogen sulfate;

(Id-iab): (2S,2'S,3S,3'S,4S,4'S,5R,5'R,6S,6'S)-6,6'-(((4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl)bis(oxy))bis(3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid);

(Id-iaab): (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(hydrogen sulfate);

or a pharmaceutically acceptable salt of any of these compounds.


3. The compound according to claim 1, wherein said compound is the compound represented by formula (Id-ia) below



(Id-ia)

or a pharmaceutically acceptable salt thereof.


4. The compound according to claim 1, wherein said compound is the compound represented by formula (Id-ib) below



(Id-ib)

or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1, wherein said compound is the compound represented by formula (Id-iab) below




(Id-iab)

or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1, wherein said compound is the compound represented by formula (Id-iaa) below


68



(Id-iiia)

or a pharmaceutically acceptable salt thereof.

- 5 7. The compound according to claim 1, wherein said compound is the compound represented by formula (Id-iiib) below




(Id-iiib)

or a pharmaceutically acceptable salt thereof.

10

8. The compound according to claim 1, wherein said compound is the compound represented by formula (Id-iiab) below



(Id-iiab)

- 15 or a pharmaceutically acceptable salt thereof.

9. The compound according to any of claims 1-8 or a pharmaceutically acceptable salt thereof, wherein said compound is on an isolated form substantially free of the compound of formula (I).

10. The compound or pharmaceutically acceptable salt thereof according to any of claims 1-9, wherein said compound or pharmaceutically acceptable salt thereof is in a solid form.

10

11. A pharmaceutically acceptable salt of a compound according to any of claims 1-10.

12. The compound or pharmaceutically acceptable salt thereof according to any of claims 1-11, for use as a medicament.

15

13. A pharmaceutical composition comprising a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof according to any one of claims 1-11, and one or more pharmaceutically acceptable excipients.

20 14. The pharmaceutical composition according to claim 13, wherein said pharmaceutical composition is an oral pharmaceutical composition such as a tablet or a capsule for oral administration.

25 15. A compound or pharmaceutically acceptable salt thereof according to any of claims 1-11, for use in the treatment of a neurodegenerative disease or disorder such as Parkinson's Disease, Huntington's disease, Restless leg syndrome or Alzheimer's disease; or a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.

16. A method for the treatment of a neurodegenerative disease or disorder such as Parkinson's Disease, Huntington's disease, Restless leg syndrome or Alzheimer's disease; or a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction; which method comprises the administration of a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof according to any of claims 1-11, to a patient in need thereof.
- 5